GigaGen: GigaGen awarded US BARDA contract valued upto $135.2 mn to develop recombinant polyclonal antibody therapies for BoNT and an additional biothreat
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint─resistant cancers, and a subsidiary of Grifols, announced that it
Read full article »
GigaGen is a biotechnology company that develops and commercializes single-cell technology-based antibody drugs to treat infectious diseases.
Read more